Clinical characteristics and management of wound foreign bodies in the ED.
Abstract
OBJECTIVES: Wound foreign body (FB) management is challenging. Little data exist describing ED management. We sought to describe case characteristics and ED management of wound FBs.
METHODS: Retrospective case series of all patients with ICD-9 code diagnosis of wound FB over 4 years in 2 EDs.
RESULTS: Four hundred ninety cases met inclusion criteria. A total of 75.6% presented within 48 hours of injury. Wounds from foreign material or stepping on something accounted for two thirds of the mechanisms. Most were wood, metal, or glass. Diagnosis was primarily by physical exam with exploration (77.6%; 95% confidence interval, 73.4%-81.5%), but 22.4% (95% confidence interval, 18.5-26.6%) were only diagnosed radiographically. X-rays missed 25% of glass and 93% of wood FBs. Eighty-nine percent were removed in the ED. Consultation was uncommon (9.6%).
CONCLUSIONS: Most, but not all, patients with wound FBs presented within 48 hours of injury and had suspicious complaints or mechanisms. Diagnosis was usually clinical but sometimes only by radiography. Radiographs were not sufficiently sensitive to reliably detect wood and glass. Most FBs were successfully removed without specialty consultation.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.